Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Meningiomas, which originate from arachnoid cells and constitute the largest subgroup of all intracranial tumors, are generally benign, yet have the capacity to progress into a higher histological grade of malignancy associated with an increase in biological aggressivity and/or capacity to recur. To elucidate meningioma pathogenesis and malignancy, we applied a holistic and network approach analyzing cDNA and tissue microarray results. A potential pathway leading to meningioma angiogenesis, apoptosis and proliferation was evidenced as well as a regulatory network of the biomarkers including Ki-67, AR, CD34, P53, c-MYC, etc. which might support clinical research. In this potential pathway, ITGB1 could be the most important "superoncogene" playing a vital role in apoptosis and proliferation, while FOXO3A, MDM4 and MT3 are important to the malignancy process. Some genes are first reported that could explain why radiation induces meningioma and why more female than male patients are affected. Further, we present the hypothesis that HIV-Tat protein might have a close relationship with meningioma pathogenesis and malignancy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/biof.5520280307DOI Listing

Publication Analysis

Top Keywords

meningioma pathogenesis
12
pathogenesis malignancy
12
holistic network
8
potential pathway
8
apoptosis proliferation
8
meningioma
5
malignancy
5
network analysis
4
analysis meningioma
4
malignancy meningiomas
4

Similar Publications

Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study.

Lancet Oncol

September 2025

MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Netwo

Background: TERT promoter mutation is a rare biomarker in meningiomas associated with aberrant TERT expression and reduced progression-free survival. Although high TERT expression is characteristic of tumours with TERT promoter mutations, it has also been observed in tumours with wildtype TERT promoters. This study aimed to investigate the prevalence and prognostic association of TERT expression in meningiomas.

View Article and Find Full Text PDF

Background: Molecular aberrations have been incorporated into tumour classification guidelines of meningioma. TERT-promoter (TERTp) mutation is associated with worse prognosis and is designated a WHO grade 3 biomarker. However, it remains unclear whether TERTp mutation is context-dependent, with other co-occurring genetic alterations potentially driving its association with prognosis.

View Article and Find Full Text PDF

Side effects of boron neutron capture therapy.

J Cancer Res Ther

September 2025

Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Boron neutron capture therapy (BNCT) is an innovative cancer treatment modality that selectively eliminates tumor cells while sparing normal tissues. Clinical studies have explored its application across various malignancies, including malignant gliomas, meningiomas, pediatric tumors, head and neck cancers, and melanomas. However, despite its therapeutic potential, BNCT is associated with various adverse effects that differ depending on the tumor type, neutron source, boron delivery agent, and treatment protocol.

View Article and Find Full Text PDF

Background: Meningiomas, the second most common intracranial tumors, account for over one-third of primary central nervous system tumors. Recent studies suggest a link between trace elements, nutrients, and tumor development. This study used Mendelian randomization (MR) to investigate causal links between trace elements, nutrients, and meningioma.

View Article and Find Full Text PDF

Investigating cochlear cellular dynamics in neurofibromatosis type 2-associated schwannomatosis: a histopathological study.

Front Neurol

August 2025

The Eaton-Peabody Laboratories, The Massachusetts Eye and Ear Department of Otolaryngology - Head and Neck Surgery, Boston, MA, United States.

Sensorineural hearing loss (SNHL) is a hallmark symptom in patients with neurofibromatosis type 2-associated schwannomatosis (NF2-SWN), a genetic condition caused by mutations in the Neurofibromin II gene that encodes the tumor suppressor protein Moesin-Ezrin-Radixin-Like Protein (Merlin; also known as schwannomin). These mutations lead to the development of various tumors, including schwannomas, ependymomas and meningiomas along the vestibular nerve and the cerebellopontine angle. Original theories attributed SNHL in NF2-SWN to the mechanical compression of the vestibulocochlear nerve from the tumor itself, in addition to secretion of toxic tumor byproducts.

View Article and Find Full Text PDF